Real-World Safety Data From the World Apheresis Association Registry for the Spectra Optia Apheresis System

Area of Science:

• Medical devices
• Hematology
• Patient safety

Background:

• The Spectra Optia Apheresis System is widely used.
• Understanding device-specific adverse events (AEs) is crucial for patient safety.
• Previous safety analyses have not been device-specific.

Purpose of the Study:

• To conduct the first device-specific analysis of AEs for the Spectra Optia Apheresis System.
• To identify AE rates, common events, and risk factors.
• To inform practitioners about potential safety concerns and improve procedure management.

Main Methods:

• Analysis of 12 years (2012-2023) of AE data from the World Apheresis Association Registry.
• Inclusion of apheresis procedures exclusively performed on the Spectra Optia system.
• Categorization of AEs by severity (mild, moderate, severe) and analysis by year, diagnosis, procedure type, vascular access, and replacement fluid.

Main Results:

• Over 51,000 procedures were analyzed.
• AE rates: mild 1.43%, moderate 2.81%, severe 0.21%.
• Lowest AE rates for red blood cell exchange and therapeutic plasma exchange.
• Common mild/moderate AEs: tingling, hypotension, vascular access issues.
• Highest mild/moderate AEs with cellular collections.
• Highest severe AEs associated with 3.5% albumin replacement fluid.

Conclusions:

• This device-specific analysis enhances understanding of Spectra Optia safety.
• Identified key variables impacting patient safety during apheresis.
• Findings support improved procedure management and patient safety protocols for this apheresis system.